BRIEF published on 04/15/2025 at 10:05, 1 year 4 months ago IOmx Therapeutics Gains Approval for IOMX-0675 Clinical Trials Immune Response IOmx Therapeutics IOMX-0675 Clinical Trial Approval Solid Tumor Therapy
BRIEF published on 04/15/2025 at 10:05, 1 year 4 months ago IOmx Therapeutics obtient l'approbation pour les essais cliniques sur IOMX-0675 Réponse Immunitaire IOmx Therapeutics IOMX-0675 Approbation Des Essais Cliniques Thérapie Des Tumeurs Solides
PRESS RELEASE published on 04/15/2025 at 10:00, 1 year 4 months ago iOmx Therapeutics Receives Regulatory Approval of Clinical Trial Application for IOMX-0675 iOmx Therapeutics receives regulatory approval for clinical trial application of IOMX-0675, a LILRB1/LILRB2 dual-targeting antibody, to reverse immune suppression in solid tumors Regulatory Approval Clinical Trial Application IOmx Therapeutics IOMX-0675 Solid Tumor
BRIEF published on 12/19/2024 at 14:05, 1 year 8 months ago IOmx Therapeutics Advances IOMX-0675 with Clinical Trial Application Cancer Treatment Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors
BRIEF published on 12/19/2024 at 14:05, 1 year 8 months ago IOmx Therapeutics fait progresser IOMX-0675 avec une application d'essai clinique Traitement Du Cancer Thérapeutique IOmx IOMX-0675 Demande D'essai Clinique Récepteurs Immunosuppresseurs
PRESS RELEASE published on 12/19/2024 at 14:00, 1 year 8 months ago iOmx Therapeutics submits Clinical Trial Application for IOMX-0675 iOmx Therapeutics submits Clinical Trial Application for IOMX-0675, a dual-targeting antibody demonstrating strong anti-tumor potential by reprogramming myeloid cells and restoring cytotoxic T cell function Clinical Trial Application IOmx Therapeutics IOMX-0675 Immunosuppressive Receptors Anti-tumor Potential
BRIEF published on 08/22/2024 at 10:05, 2 years ago IOmx Therapeutics Initiates Phase Ib with OMX-0407 Cancer Therapy Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 08/22/2024 at 10:05, 2 years ago IOmx Therapeutics lance la phase Ib avec OMX-0407 Essai Clinique Thérapie Contre Le Cancer OMX-0407 Phase Ib Thérapeutique IOmx
PRESS RELEASE published on 08/22/2024 at 10:00, 2 years ago iOmx Therapeutics Initiates Phase Ib with OMX-0407 iOmx Therapeutics initiates Phase Ib clinical trial with OMX-0407, showing favorable safety profile and anti-tumor activity in solid tumors. Expansion phase opens in kidney cancer and angiosarcoma Solid Tumors Clinical Trial IOmx Therapeutics OMX-0407 Phase Ib
BRIEF published on 06/27/2024 at 10:05, 2 years 1 month ago IOmx Therapeutics Appoints Florian Schmid as New Chief Financial Officer Chief Financial Officer Biopharmaceutical Leadership IOmx Therapeutics Florian Schmid
Published on 08/24/2026 at 23:00, 4 hours 44 minutes ago Galway Metals Engages Simone Capital Corp. for Investor Relations Services
Published on 08/24/2026 at 19:00, 8 hours 44 minutes ago Rio Grande Resources Announces Closing of Over-Subscribed Non-Brokered Private Placement for $2.55 Million
Published on 08/24/2026 at 16:00, 11 hours 44 minutes ago Critical Elements - le programme de forage estival de 10 000 mètres À rose ouest continu de livrer des résultats positifs
Published on 08/24/2026 at 16:00, 11 hours 44 minutes ago Critical Elements' 10,000-Meter Summer Drill Program at Rose West Continues to Deliver Positive Results
Published on 08/24/2026 at 15:00, 12 hours 44 minutes ago Silver Storm Announces Upsize of Non-Brokered Private Placement to $15.0 Million
Published on 08/25/2026 at 01:05, 2 hours 39 minutes ago Sogang University Opens a Full-Tuition Path for International STEM Graduate Students in Seoul
Published on 08/24/2026 at 23:51, 3 hours 52 minutes ago EQS-Adhoc: Northern Data Group in advanced negotiations with RUM Group Inc. regarding a long-term lease agreement of its site in Maysville
Published on 08/24/2026 at 22:15, 5 hours 29 minutes ago Amrize Appoints Sam Poletti as Chief Financial Officer
Published on 08/24/2026 at 22:05, 5 hours 39 minutes ago Nebius Group announces closing of private offering of convertible senior notes, with aggregate gross proceeds of approximately $5.75 billion
Published on 08/24/2026 at 21:29, 6 hours 15 minutes ago Cozy Life Sim Animula Nook Brings a New Beta to gamescom 2026 - Playable Hands-On Demos at the Tencent Games Booth
Published on 08/24/2026 at 18:00, 9 hours 44 minutes ago Publication du nombre d’actions composant le capital et du nombre total de droits de vote au 31 juillet 2026
Published on 08/24/2026 at 18:00, 9 hours 44 minutes ago Outstanding shares and voting rights statement at 31 July 2026
Published on 08/24/2026 at 17:59, 9 hours 44 minutes ago Saint-Gobain strengthens its positioning in construction chemicals and light construction in Latin America
Published on 08/24/2026 at 17:59, 9 hours 44 minutes ago Saint-Gobain se renforce dans la chimie de la construction et la construction légère en Amérique latine
Published on 08/24/2026 at 17:45, 9 hours 59 minutes ago Déclaration hebdomadaire de rachat d'actions
